NP Theresa Stukus and NP Nelli Zafman discuss the practical challenges patients with metastatic triple-negative breast cancer ...

The U.S. Food and Drug Administration (FDA) approved tucatinib (Tukysa, Seagen Inc., a subsidiary of Pfizer) on October 7, ...

NP Theresa Stukus and NP Nelli Zafman discuss practical strategies for preventing, monitoring, and managing oral and ocular toxicities in patients with metastatic triple-negative breast cancer (mTNBC) ...

In observation of National PA Week, Moffitt PA Mark Honor details top-of-license nursing collaboration and outpatient ...

An FDA advisory panel voted to approve GRAIL's Galleri multi-cancer early detection test for adults 50+. Read key oncology ...

Following WCLC 2026, Katherine Kuhns details how perioperative immunotherapy, AI patient tools, and wearables are ...

Adding atezolizumab to adjuvant FOLFOX halved the risk of recurrence or death in ATOMIC, with more grade 3 to 4 adverse events. The FDA has approved atezolizumab (Tecentriq) in combination with a ...

At ASTRO 2026, Dr. Erica Braschi Jordan details toxicity tracking, physical therapy referral, and quality of life in proton ...

The selective internal radiation therapy SIR-Spheres has been approved by the FDA for use in patients with unresectable hepatocellular carcinoma. The FDA has approved SIR-Spheres Y-90 resin ...

September marks Gynecologic Cancer Awareness Month, an annual observation focused on increasing public and clinical awareness of gynecologic malignancies, including ovarian, endometrial, cervical, ...

NP Theresa Stukus and NP Nelli Zafman discuss long-term management considerations for a patient with metastatic ...